Bibliography Links Contact
RC: Clodronate is an orally administered biphosphonate which is remarkably safe and free of side-effects and has been proven in several trials to significantly reduce metastases (bone and organ) as well as enhance survival in breast cancer. Breast cancer patient regardless of node and estrogen status should consider taking this on an adjuvant basis after chemotherapy and/or radiotherapy to reduce the chance of metastases and improve survival with the added bonus of reducing the risk of osteoporosis. The drug was in trial in the US. It is available as a compassionate import by prescription from Europe and Canada, but is cheapest and more readily available from Canada. We are experienced in the use of the drug and can advise its use in specific cases upon consultation.
The Present and future role of biphosphonates in the management of patients with breast cancer is an online review by Brown and Coleman of the Cancer Research Center of Weston Park Hospital of Sheffield, U.K .

Safety profile of oral clodronate during long-term use in primary breast cancer patients represents experience on adverse effects of over a thousand women taking clodronate at 1600mg a day for 5+ years.

Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer is Journal of Clinical Oncology paper reporting on the 5+ years median follow-up by the Royal Marsden National Health Service Trust and University of Sheffield group in the U.K. on outcome of 1,069 women treated with clodronate demonstrating significant reduction in metastasis (p<0.257) as well as advantage in survival (p=.047).

Preventing Breast Cancer Cell Metastasis as cited on Anne Fonfa’s Annie Appleseed Project website.

Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment by Ingo J. Diel, et al. is a landmark German study from the University of Heidelberg published 1998 in the New England Journal of Medicine which established that clodronate reduces metastases (p<.001) as well as enhances survival (p = .001)

Randomized phase III Trial:
“Clodronate with or without chemotherapy and/or tamoxifen in treating women with stage I or stage II breast cancer sponsored by the National Surgical Adjuvant Breast and Bowel Projecct, NCI, Southwest Oncology Group and North Central Cancer Treatment Group”